top of page

Immunis - A CHV portfolio raises U$10M Series A

Immunis - A CHV portfolio raises U$10M Series A

23-08-03, 12:00 a.m.

Immunis Inc., a private biotechnology company developing a novel treatment for age and disease-related immune decline, has closed a $10M Series A First Closing financing led by Remiges Ventures with participation by several other healthcare investment firms. Strategic investor, Continuum Health Ventures, which supports thesis-driven startups at the intersection of health and technology in the digital health and longevity sectors, also joined the round. Proceeds will support clinical assessment of Immunis’ immunomodulatory secretome product in an FDA-awarded Phase 1/2a clinical trial targeting muscle atrophy, which is an age, disuse and disease-associated condition experienced by 100% of the population.

This is a paragraph. It is connected to a CMS collection through a dataset. Click “Edit Text” to update content from the connected collection.

bottom of page